Patrik Gilje1, Sasha Koul2, Jakob Hartvig Thomsen3, Yvan Devaux4, Hans Friberg5, Michael Kuiper6, Janneke Horn7, Niklas Nielsen8, Tomasso Pellis9, Pascal Stammet10, Matthew P Wise11, Jesper Kjaergaard3, Christian Hassager3, David Erlinge2. 1. Department of Cardiology, Clinical Sciences, Lund University, Lund, Sweden. Electronic address: patrik.gilje@med.lu.se. 2. Department of Cardiology, Clinical Sciences, Lund University, Lund, Sweden. 3. The Heart Centre, Copenhagen University Hospital, Copenhagen, Denmark. 4. Laboratory of Cardiovascular Research, Public Research Centre - Health (CRP Santé), Luxembourg. 5. Department of Anesthesia and Intensive Care, Skåne University Hospital, Lund University, Lund, Sweden. 6. Department of Intensive Care, Leeuwarden Medical Centrum, Leeuwarden, The Netherlands. 7. Department of Intensive Care, Academic Medical Center, Amsterdam, The Netherlands. 8. Department of Anesthesia and Intensive Care, Helsingborg Hospital, Helsingborg, Sweden. 9. Intensive Care Unit, Santa Maria Degli Angeli, Pordenone, Italy. 10. Department of Anesthesia and Intensive Care, Centre Hospitalier de Luxembourg, Luxembourg. 11. Department of Intensive Care, University Hospital of Wales, Cardiff, United Kingdom.
Abstract
AIM OF THE STUDY: Predicting outcome of unconscious patients after successful resuscitation is challenging and better prognostic markers are highly needed. Ischemic heart disease is a common cause of out-of-hospital cardiac arrest (OHCA). Whether or not high-sensitivity troponin T (hs-TnT) is a prognostic marker among survivors of OHCA with both ischemic and non-ischemic aetiologies remains to be determined. We sought to evaluate the ability of hs-TnT to prognosticate all-cause mortality, death due to cardiovascular causes or multi-organ failure and death due to cerebral causes after OHCA. The influence of the level of target temperature management on hs-TnT as a marker of infarct size was also assessed. METHODS: A total of 699 patients from the targeted temperature management (TTM) trial were included and hs-TnT was analyzed in blood samples from 24, 48 and 72h after return of spontaneous circulation (ROSC). The endpoints were 180 day all-cause mortality, death due to cardiovascular causes or multi-organ failure and death due to cerebral causes. Subgroups based on the initial ECG after ROSC (STEMI vs all other ECG presentations) were analyzed. RESULTS: Hs-TnT was independently associated with all-cause mortality which was driven by death due to cardiovascular causes or multi-organ failure and not cerebral causes (at 48h: OR 1.10, CI 1.01-1.20, p<0.05). Hs-TnT was also an independent predictor of death due to cardiovascular causes or multi-organ failure (at 48h: OR 1.13, CI 1.01-1.26, p<0.05). In patients with STEMI, hs-TnT was independently associated with death due to cardiovascular causes or multi-organ failure (at 48h: OR 1.47, CI 1.10-1.95, p<0.01). Targeted temperature management at 33°C was not associated with hs-TnT compared to 36°C. CONCLUSIONS: After OHCA due to both ischemic and non-ischemic causes, hs-TnT is an independent marker of both all-cause mortality and death due to cardiovascular causes or multi-organ failure. Targeted temperature management at 33°C did not reduce hs-TnT compared to 36°C. Hs-TnT may be a marker of poor prognosis after OHCA and this should be taken into consideration in patients that present with high troponin levels. TRIAL REGISTRATION: The TTM-trial is registered and accessible at Clinicaltrials.gov (identifier: NCT01020916).
AIM OF THE STUDY: Predicting outcome of unconscious patients after successful resuscitation is challenging and better prognostic markers are highly needed. Ischemicheart disease is a common cause of out-of-hospital cardiac arrest (OHCA). Whether or not high-sensitivity troponin T (hs-TnT) is a prognostic marker among survivors of OHCA with both ischemic and non-ischemic aetiologies remains to be determined. We sought to evaluate the ability of hs-TnT to prognosticate all-cause mortality, death due to cardiovascular causes or multi-organ failure and death due to cerebral causes after OHCA. The influence of the level of target temperature management on hs-TnT as a marker of infarct size was also assessed. METHODS: A total of 699 patients from the targeted temperature management (TTM) trial were included and hs-TnT was analyzed in blood samples from 24, 48 and 72h after return of spontaneous circulation (ROSC). The endpoints were 180 day all-cause mortality, death due to cardiovascular causes or multi-organ failure and death due to cerebral causes. Subgroups based on the initial ECG after ROSC (STEMI vs all other ECG presentations) were analyzed. RESULTS: Hs-TnT was independently associated with all-cause mortality which was driven by death due to cardiovascular causes or multi-organ failure and not cerebral causes (at 48h: OR 1.10, CI 1.01-1.20, p<0.05). Hs-TnT was also an independent predictor of death due to cardiovascular causes or multi-organ failure (at 48h: OR 1.13, CI 1.01-1.26, p<0.05). In patients with STEMI, hs-TnT was independently associated with death due to cardiovascular causes or multi-organ failure (at 48h: OR 1.47, CI 1.10-1.95, p<0.01). Targeted temperature management at 33°C was not associated with hs-TnT compared to 36°C. CONCLUSIONS: After OHCA due to both ischemic and non-ischemic causes, hs-TnT is an independent marker of both all-cause mortality and death due to cardiovascular causes or multi-organ failure. Targeted temperature management at 33°C did not reduce hs-TnT compared to 36°C. Hs-TnT may be a marker of poor prognosis after OHCA and this should be taken into consideration in patients that present with high troponin levels. TRIAL REGISTRATION: The TTM-trial is registered and accessible at Clinicaltrials.gov (identifier: NCT01020916).
Authors: Ibrahim Akin; Michael Behnes; Julian Müller; Jan Forner; Mohammad Abumayyaleh; Kambis Mashayekhi; Muharrem Akin; Thomas Bertsch; Kathrin Weidner; Jonas Rusnak; Dirk Große Meininghaus; Maximilian Kittel; Tobias Schupp Journal: J Clin Med Date: 2022-05-25 Impact factor: 4.964
Authors: Yvan Devaux; Antonio Salgado-Somoza; Josef Dankiewicz; Adeline Boileau; Pascal Stammet; Anna Schritz; Lu Zhang; Mélanie Vausort; Patrik Gilje; David Erlinge; Christian Hassager; Matthew P Wise; Michael Kuiper; Hans Friberg; Niklas Nielsen Journal: Theranostics Date: 2017-06-25 Impact factor: 11.556
Authors: Adeline Boileau; Antonio Salgado Somoza; Josef Dankiewicz; Pascal Stammet; Patrik Gilje; David Erlinge; Christian Hassager; Matthew P Wise; Michael Kuiper; Hans Friberg; Niklas Nielsen; Yvan Devaux Journal: Dis Markers Date: 2019-06-02 Impact factor: 3.434
Authors: Alf Inge Larsen; Anders Morten Grejs; Simon Tilma Vistisen; Kristian Strand; Øyvind Skadberg; Anni Nørgaard Jeppesen; Christophe H V Duez; Hans Kirkegaard; Eldar Søreide Journal: BMC Cardiovasc Disord Date: 2022-07-30 Impact factor: 2.174
Authors: Antti Saraste; Haitham Ballo; Olli Arola; Ruut Laitio; Juhani Airaksinen; Marja Hynninen; Minna Bäcklund; Emmi Ylikoski; Johanna Wennervirta; Mikko Pietilä; Risto O Roine; Veli-Pekka Harjola; Jussi Niiranen; Kirsi Korpi; Marjut Varpula; Harry Scheinin; Mervyn Maze; Tero Vahlberg; Timo Laitio Journal: Crit Care Explor Date: 2021-07-29